Page 1857 · The specialty pharmacy's day-to-day workflow for submitting and tracking prior authorization requests for high-cost specialty medications
Specialty medications — biologics, oncology infusions, gene and cell therapies, and other complex products — routinely carry price tags of thousands to hundreds of thousands of dollars per course of treatment. Before a payer commits to covering that cost, it typically requires prior authorization (PA): a formal review confirming that the medication is medically necessary for this specific patient and being used in a clinically appropriate way. For the specialty pharmacy, PA is not a paperwork afterthought — it is the gate that stands between the prescriber's order and the patient actually receiving the drug.
A payer's PA criteria for a specialty medication are drug- and plan-specific, but they generally exist to confirm three things before the payer agrees to pay:
• Medical necessity — does the patient's diagnosis and clinical picture actually match an approved or evidence-supported use for this medication? • Appropriate positioning — has the patient tried and failed (or is otherwise unsuitable for) less expensive first-line options, where the plan requires that step? • Correct dosing and setting — is the requested dose, frequency, and site of care consistent with labeling and the payer's coverage policy?
Because the underlying medication is expensive and often used for serious or chronic conditions, payers treat this review as a routine condition of coverage rather than an exception — which is why the specialty pharmacy builds PA submission into its standard dispensing workflow rather than treating it as a rare, ad-hoc task.
Specialty pharmacies are frequently the party best positioned to run the PA process, for a practical reason: they sit at the intersection of the prescription, the payer relationship, and the patient's urgency to start therapy. A physician's office may write dozens of specialty prescriptions a month across many different payers and drugs, each with its own documentation checklist — while the specialty pharmacy's intake and prior-authorization staff handle this volume every day and know each payer's expectations for the specific medication.
That specialization is what this simulation focuses on: not the underlying technical standard that carries a PA request from system to system, but the practical, hands-on submission workflow — gathering the right documentation, submitting it correctly, tracking it, and responding when the payer asks for more — that determines how quickly a patient actually gets their medication.
A companion page on this site, Prior Authorization Workflow, covers the technical interoperability side of PA — the FHIR Prior Authorization Support (PAS) standard and the CMS interoperability rule that increasingly automate the electronic exchange of these requests. This page focuses on the operational side: what specialty pharmacy staff actually do, day to day, to get a PA submitted, tracked, and resolved.
Every payer, and often every plan within a payer, maintains its own PA criteria for a given specialty medication. Before a submission can go anywhere, specialty pharmacy staff must pull together the exact set of clinical evidence that particular payer expects to see — no more, no less — because an incomplete packet is one of the most common reasons a request stalls or gets returned for more information.
While exact checklists differ, the clinical documentation a specialty pharmacy assembles for a PA submission generally falls into a few recurring categories:
• Diagnosis codes — the ICD-10 code(s) supporting the medical condition the medication is being prescribed for, matched against the payer's covered-diagnosis list for that drug. • Relevant lab or test results — objective clinical values (for example, disease-activity scores, biomarker levels, or imaging findings) that demonstrate the severity or presence of the condition being treated. • Prior therapy history — a record of medications previously tried, at what doses and for how long, and why they were discontinued (inadequate response, intolerance, contraindication) — required when the payer's policy calls for step therapy.
Staff typically pull this information from the prescriber's chart notes, lab systems, and pharmacy dispensing history, then organize it against the specific payer's published or portal-based PA criteria for that medication.
Submitting a generic packet — the same set of documents regardless of which payer is reviewing the request — is a common source of delay. A payer that requires a specific rheumatologic disease-activity score, for instance, will not accept a general progress note in its place; a payer that requires documented failure of two prior agents will not accept documentation of only one.
Experienced specialty pharmacy staff keep track of these payer-specific nuances so that the packet assembled in this stage is built to satisfy the reviewer on the first pass — because every missing element that surfaces later becomes a request for additional information, and every such request adds days before the patient can start therapy.
Once the documentation package is complete, it is submitted to the payer through whatever channel that payer supports — a payer portal, fax, or an electronic prior authorization pathway — and enters an initial review queue. From this point, the coverage determination is made by the payer against its own internal, drug-specific clinical criteria.
A submission that is clinically complete can still be delayed if it goes to the wrong channel, is missing a required cover form, or is addressed to the wrong plan within a payer's book of business. Specialty pharmacy intake staff verify:
• The correct payer and plan (including any specialty pharmacy network or benefit-manager routing specific to that plan) • The correct submission channel for that payer's PA process • That all required forms and attachments are included in the format the payer expects
Getting this handoff right the first time is what allows the clock to start on the payer's own review timeline, rather than losing days to a rejected or misrouted submission.
Once received, the request enters the payer's initial review queue. A reviewer — often following an algorithmic or nurse/pharmacist-led protocol — compares the submitted clinical evidence against that payer's specific coverage policy for the medication. From this review, three broad outcomes are possible:
• Approval — the request is authorized, typically for a defined duration or number of doses. • Denial — the request does not meet the payer's criteria as submitted. • Request for additional information — the reviewer needs further clinical detail before a determination can be made.
The specialty pharmacy generally has limited visibility into the payer's internal process once the packet is submitted, which is why the next stage — actively tracking status — becomes so important.
A submitted PA request does not resolve itself. Specialty pharmacy staff actively monitor the status of pending requests and, when a payer comes back asking for additional information, respond as quickly as possible — because every day a request sits unanswered is a day the patient's access to therapy is delayed.
Once a request is submitted, staff typically log it into a tracking worklist or their pharmacy management system, noting the submission date, payer, medication, and expected review window. From there, the work is ongoing:
• Checking payer portals or fax responses for status updates • Calling payer PA departments when a request has been pending unusually long with no update • Flagging cases that are approaching a point where the patient's existing medication supply will run out, so they can be prioritized for follow-up
This is largely manual, relationship- and process-driven work — the specialty pharmacy acting as the patient's advocate inside a review process it does not control.
A request for additional information effectively pauses the payer's clock until the pharmacy (often working with the prescriber's office) supplies what was asked for. Because this pause adds directly to the patient's wait, responsiveness at this step is one of the highest-leverage actions specialty pharmacy staff can take:
• Confirming exactly what the payer is asking for, rather than resubmitting the same information • Coordinating quickly with the prescriber's office to obtain the specific chart note, lab value, or attestation requested • Resubmitting through the correct channel promptly, rather than letting the request sit in a queue
The illustrative threshold used elsewhere on this page — flagging a submission as delayed after roughly a week with no movement — reflects this same principle: the earlier a stalled request is caught, the sooner it can be pushed forward.
From the patient's perspective, the entire PA process is invisible except for one thing: how long it takes before they can pick up their medication. Every stage of this simulator ultimately serves that single outcome — minimizing the time between the prescriber's order and the patient holding their therapy.
Every PA request eventually reaches a determination. An approval opens the gate and clears the medication for dispensing. A denial closes it — but not permanently: a defined appeal pathway exists for prescribers who believe the denial does not reflect the patient's actual clinical situation, and specialty pharmacies routinely support that appeal process.
An approval typically specifies the authorized duration or quantity of therapy and any conditions attached to continued coverage (for example, periodic reauthorization or ongoing monitoring requirements). At this point the gate opens: the specialty pharmacy can proceed to dispense the medication, and staff shift their attention to coordinating delivery, patient education, and — where relevant — scheduling the next reauthorization well before the current approval expires.
A denial means the payer determined the submitted request did not meet its coverage criteria. This is not necessarily the end of the road: payers are generally required to provide an appeal pathway, and prescribers who believe the denial was unwarranted — because of a documentation gap, a criteria mismatch, or a genuine clinical nuance the initial reviewer missed — can pursue it.
Specialty pharmacy staff commonly support this process by:
• Reviewing the denial reason with the prescriber's office to identify what additional evidence or clarification might address it • Assembling supplemental clinical documentation for the appeal submission • Tracking the appeal through its own review timeline, just as the original request was tracked
Because an appeal adds further time before the patient can start therapy, prescribers and pharmacy staff weigh whether the clinical case is strong enough to warrant pursuing it versus considering a covered alternative therapy.
The appeal pathway exists precisely because prior authorization review, while systematic, is not infallible — criteria can be misapplied, documentation can be misread, and clinical nuance does not always translate cleanly into a checklist. A denial is a signal to reassess the submission, not necessarily a final answer.